Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Protagenic Therapeutics, Inc.\new | d140769d10q.htm |
| EX-31.2 - EX-31.2 - Protagenic Therapeutics, Inc.\new | d140769dex312.htm |
| EX-31.1 - EX-31.1 - Protagenic Therapeutics, Inc.\new | d140769dex311.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES OXLEY ACT OF 2002
In connection with the Quarterly Report of Atrinsic, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Edward Gildea, Chief Executive Officer, and David Horin, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
| Date: March 11, 2016 | By: | /s/ Garo H. Armen | ||
| Garo H. Armen, PhD | ||||
| Executive Chairman | ||||
| (Principal Executive Officer) |
| Date: March 11, 2016 | By: | /s/ Alexander K. Arrow | ||
| Alexander K. Arrow, MD, CFA | ||||
| Chief Financial Officer | ||||
| (Principal Financial Officer) |